APO RESEARCH · REPORT
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Product & engineering
Understand the product.
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
Selected research
Industry Research
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Research Report 2026
Market perspective
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Read the full market overview
Report Scope
This report quantifies the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Type
CellSearch
Others
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CellSearch
- Others
Applications
- Breast Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Other Cancers Diagnosis and Treatment
Companies covered
- Janssen
- Qiagen
- Advanced Cell Diagnostics
- ApoCell
- Biofluidica
- Clearbridge Biomedics
- CytoTrack
- Celsee
- Fluxion
- Gilupi
- Cynvenio
- On-chip
- YZY Bio
- BioView
- Fluidigm
- Ikonisys
- AdnaGen
- IVDiagnostics
- Miltenyi Biotec
- ScreenCell
- Silicon Biosystems
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CellSearch
- 2.2.3 Others
- 2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Breast Cancer Diagnosis and Treatment
- 2.3.3 Prostate Cancer Diagnosis and Treatment
- 2.3.4 Colorectal Cancer Diagnosis and Treatment
- 2.3.5 Lung Cancer Diagnosis and Treatment
- 2.3.6 Other Cancers Diagnosis and Treatment
- 2.4 Assumptions and Limitations
3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Type
- 3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Type (2021-2026)
- 3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2027-2032)
4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Application
- 4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Application (2021-2026)
- 4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Perspective (2021-2032)
- 5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Growth Trends by Region
- 5.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Region (2021-2026)
- 5.2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Region (2027-2032)
- 5.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
- 5.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
- 5.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
- 5.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
- 5.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players by Revenue
- 6.1.1 Global Top Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players by Revenue (2021-2026)
- 6.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2021-2026)
- 6.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Head Office and Area Served
- 6.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players, Product Type & Application
- 6.5 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturers Established Date
- 6.6 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2021-2032)
- 7.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2021-2026)
- 7.4 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2021-2032)
- 8.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2021-2026)
- 8.4 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2021-2032)
- 9.2 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2021-2032)
- 10.2 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2021-2026)
- 10.4 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2021-2032)
- 11.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Janssen
- 12.1.1 Janssen Company Information
- 12.1.2 Janssen Business Overview
- 12.1.3 Janssen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.1.5 Janssen Recent Developments
- 12.2 Qiagen
- 12.2.1 Qiagen Company Information
- 12.2.2 Qiagen Business Overview
- 12.2.3 Qiagen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.2.5 Qiagen Recent Developments
- 12.3 Advanced Cell Diagnostics
- 12.3.1 Advanced Cell Diagnostics Company Information
- 12.3.2 Advanced Cell Diagnostics Business Overview
- 12.3.3 Advanced Cell Diagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.3.5 Advanced Cell Diagnostics Recent Developments
- 12.4 ApoCell
- 12.4.1 ApoCell Company Information
- 12.4.2 ApoCell Business Overview
- 12.4.3 ApoCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.4.5 ApoCell Recent Developments
- 12.5 Biofluidica
- 12.5.1 Biofluidica Company Information
- 12.5.2 Biofluidica Business Overview
- 12.5.3 Biofluidica Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.5.5 Biofluidica Recent Developments
- 12.6 Clearbridge Biomedics
- 12.6.1 Clearbridge Biomedics Company Information
- 12.6.2 Clearbridge Biomedics Business Overview
- 12.6.3 Clearbridge Biomedics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.6.5 Clearbridge Biomedics Recent Developments
- 12.7 CytoTrack
- 12.7.1 CytoTrack Company Information
- 12.7.2 CytoTrack Business Overview
- 12.7.3 CytoTrack Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.7.5 CytoTrack Recent Developments
- 12.8 Celsee
- 12.8.1 Celsee Company Information
- 12.8.2 Celsee Business Overview
- 12.8.3 Celsee Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.8.5 Celsee Recent Developments
- 12.9 Fluxion
- 12.9.1 Fluxion Company Information
- 12.9.2 Fluxion Business Overview
- 12.9.3 Fluxion Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.9.5 Fluxion Recent Developments
- 12.10 Gilupi
- 12.10.1 Gilupi Company Information
- 12.10.2 Gilupi Business Overview
- 12.10.3 Gilupi Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.10.5 Gilupi Recent Developments
- 12.11 Cynvenio
- 12.11.1 Cynvenio Company Information
- 12.11.2 Cynvenio Business Overview
- 12.11.3 Cynvenio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.11.5 Cynvenio Recent Developments
- 12.12 On-chip
- 12.12.1 On-chip Company Information
- 12.12.2 On-chip Business Overview
- 12.12.3 On-chip Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.12.5 On-chip Recent Developments
- 12.13 YZY Bio
- 12.13.1 YZY Bio Company Information
- 12.13.2 YZY Bio Business Overview
- 12.13.3 YZY Bio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.13.5 YZY Bio Recent Developments
- 12.14 BioView
- 12.14.1 BioView Company Information
- 12.14.2 BioView Business Overview
- 12.14.3 BioView Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.14.5 BioView Recent Developments
- 12.15 Fluidigm
- 12.15.1 Fluidigm Company Information
- 12.15.2 Fluidigm Business Overview
- 12.15.3 Fluidigm Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.15.5 Fluidigm Recent Developments
- 12.16 Ikonisys
- 12.16.1 Ikonisys Company Information
- 12.16.2 Ikonisys Business Overview
- 12.16.3 Ikonisys Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.16.5 Ikonisys Recent Developments
- 12.17 AdnaGen
- 12.17.1 AdnaGen Company Information
- 12.17.2 AdnaGen Business Overview
- 12.17.3 AdnaGen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.17.5 AdnaGen Recent Developments
- 12.18 IVDiagnostics
- 12.18.1 IVDiagnostics Company Information
- 12.18.2 IVDiagnostics Business Overview
- 12.18.3 IVDiagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.18.5 IVDiagnostics Recent Developments
- 12.19 Miltenyi Biotec
- 12.19.1 Miltenyi Biotec Company Information
- 12.19.2 Miltenyi Biotec Business Overview
- 12.19.3 Miltenyi Biotec Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.19.5 Miltenyi Biotec Recent Developments
- 12.20 ScreenCell
- 12.20.1 ScreenCell Company Information
- 12.20.2 ScreenCell Business Overview
- 12.20.3 ScreenCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.20.5 ScreenCell Recent Developments
- 12.21 Silicon Biosystems
- 12.21.1 Silicon Biosystems Company Information
- 12.21.2 Silicon Biosystems Business Overview
- 12.21.3 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2021-2026)
- 12.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
- 12.21.5 Silicon Biosystems Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst